UCB – One of the World’s Biggest Public Companies

Biopharmaceutical Company UCB pic
Biopharmaceutical Company UCB
Image: ucb.com

Joining UCB in November 2012 as executive vice president and general counsel, Anna Richo previously held senior executive positions at other pharmaceutical and health care companies. The corporation that Anna Richo represents is listed by Forbes magazine on it Global 2000 List of companies.

Biopharmaceutical company UCB SA focuses on the fields of immunology and central nervous system disorders. It engages in research and development as well as commercialization of new drugs and solutions to help people suffering from severe diseases of the central nervous system or the immune system.

Its main immunology product is Cimzia, which is used to treat Crohn’s disease, axial spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis. UCB’s main neurology products include Briviact, Vimpat, and Keppra, which are all used for the treatment of epilepsy, and Neupro, which is used to treat Parkinson’s disease and restless legs syndrome.

UCB reaches millions of patients around the world with its products and solutions. It has more than 7,500 employees globally and does business in around 40 countries. Listed on the Euronext, it generated revenues of €3.8 billion in 2015.

UCB was founded in 1928 and is based in Brussels, Belgium.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s